Chief Medical Officer Provides Overview of Recent Positive Clinical Patient Outcomes
Demonstrates Prolonged Progression Free Survival of Two Patients in Acclaim-1 and Partial Remission from Maintenance Therapy in Acclaim-3
Expands on the previously granted patents covering the use of REQORSA in combination with immune checkpoint inhibitors
Presentation to Highlight the Company’s Gene Therapies for Cancer and Diabetes